ALX Oncology posts Q2 2026 results, reaffirms mid-2027 ASPEN-09-Breast readout
The company also detailed new HER2-positive breast cancer data, an on-track ALX2004 safety readout, and $153.4 million in cash.
ALX Oncology Holdings Inc. reported second quarter 2026 results and a corporate update on August 6, 2026. The company said enrollment in the ongoing ASPEN-09-Breast Phase 2 trial evaluating evorpacept in combination with trastuzumab remains on track, with topline data from 80 patients expected in mid-2027.1
In May, the company presented new findings at ESMO Breast Cancer 2026 from a Phase 1b/2 study pairing its CD47-inhibitor evorpacept with Jazz Pharmaceuticals' zanidatamab, marketed as ZIIHERA. The new data demonstrated promising and durable responses in heavily pre-treated metastatic breast cancer patients previously treated with ENHERTU (fam-trastuzumab deruxtecan-nxki), particularly among patients with centrally confirmed HER2-positive disease and high CD47 expression.1
For its second program, ALX Oncology said enrollment continues in the dose-escalation portion of the Phase 1 trial of ALX2004, a novel antibody-drug conjugate for EGFR-expressing solid tumors, and is on track to report safety data in the second half of 2026.1
On leadership, the company said in June it strengthened its leadership team and Board of Directors with the appointments of Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel, with Garland a Board member since 2022 bringing more than three decades of biopharmaceutical experience, and Listgarten adding legal, governance and business development expertise.1
On financing, ALX Oncology said in June it refinanced its existing $10 million debt with HSBC Ventures USA Inc. and secured the ability to draw up to an additional $20 million at its discretion through the end of June 2028.1 The agreement in total provides for a secured multi-tranche term loan facility of up to $50 million, of which $10 million is uncommitted.1
As of June 30, 2026, cash, cash equivalents and investments were $153.4 million, which the company believes is sufficient to fund planned operations through the first half of 2028.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.